+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Polycystic Ovarian Syndrome Treatment Market by Treatment Type, Drug Class, Route Of Administration, Distribution Channel, End User, Patient Type - Global Forecast 2025-2030- Product Image
Polycystic Ovarian Syndrome Treatment Market by Treatment Type, Drug Class, Route Of Administration, Distribution Channel, End User, Patient Type - Global Forecast 2025-2030- Product Image
Sale

Polycystic Ovarian Syndrome Treatment Market by Treatment Type, Drug Class, Route Of Administration, Distribution Channel, End User, Patient Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5666528
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The polycystic ovarian syndrome treatment market is advancing as healthcare providers focus on integrated clinical strategies, driven by increasing awareness of the disorder's broader health implications. This complex ecosystem sees innovation across therapy types, delivery routes, and digital health applications, supporting tailored approaches and improved patient experiences.

Market Snapshot: Polycystic Ovarian Syndrome Treatment Market

The polycystic ovarian syndrome treatment market grew from USD 3.45 billion in 2024 to USD 3.68 billion in 2025. It is expected to continue growing at a CAGR of 6.72%, reaching USD 5.09 billion by 2030. This sustained expansion reflects rising demand for patient-centric solutions, advanced pharmacological therapies, and evolving care models. Shifting regulatory frameworks and digital healthcare integration are accelerating access, enabling providers to address more varied patient needs and optimize care delivery around the world.

Scope & Segmentation

This report delivers in-depth insight into the polycystic ovarian syndrome treatment market, detailing market structure, therapies, and regional nuances. The study is structured to guide stakeholders through actionable segmentation and industry coverage.

  • Treatment Type: Lifestyle management, pharmacological treatment, surgical interventions such as bariatric surgery and ovarian drilling.
  • Drug Class: Anti-androgens (flutamide, spironolactone), insulin-sensitizing agents (metformin, thiazolidinediones), and oral contraceptives (combined oral, progestin-only pills).
  • Route of Administration: Injectable therapies (intramuscular, subcutaneous), oral, and topical formats.
  • Distribution Channel: Hospital pharmacies, online pharmacies, and retail pharmacies.
  • End User: Clinics, hospitals, specialty centers, homecare environments.
  • Patient Type: Adolescents (16–18 years, under 18 years), adults (18–35, 36–45 years).
  • Geographical Coverage: Americas (including United States, Canada, Latin America), Europe, Middle East & Africa (including United Kingdom, Germany, France, and others), Asia-Pacific (with key markets like China, India, Japan, Australia, and Southeast Asia).
  • Key Players: Bayer AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., Ferring International Center S.A., Dr. Reddy’s Laboratories Limited, GlaxoSmithKline plc, Merck KGaA, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Limited.

Key Takeaways for Decision-Makers

  • Precision medicine and personalized regimens are becoming central, leveraging advancements in genomics and patient phenotyping for optimized outcomes.
  • Dietary and lifestyle management remain foundational, but digital health tools and remote monitoring foster better adherence and patient engagement.
  • The market’s complexity is fueled by an expanding array of drug classes and administration options, allowing for greater alignment to individual patient profiles.
  • Collaborative care models are integrating the expertise of endocrinologists, reproductive specialists, nutritionists, and behavioral health professionals, supporting holistic approaches.
  • Supply chain resilience and flexible procurement strategies are paramount due to evolving trade and tariff environments, particularly in key import markets.
  • Emerging technologies, including AI-driven analytics and wearable devices, are increasingly influencing competitive differentiation and treatment delivery.

Tariff Impact and Supply Chain Adaptation

Recent United States tariff measures on pharmaceutical ingredients and medical devices have increased costs for key components in PCOS therapies. Manufacturers are evolving sourcing strategies, considering domestic partnerships and regional production to counter supply chain risks. The tariff environment has also encouraged evaluation of group purchasing and alternative formulations less exposed to import duties. These shifts require manufacturers and health systems to remain flexible and anticipate ongoing adjustments in cost structures.

Methodology & Data Sources

The analysis combines extensive secondary research from published literature, regulatory filings, and clinical trial registries, reinforced by primary interviews with endocrinologists, gynecologists, industry experts, and payers. Primary surveys, digital health data, and regional market assessments contribute granularity. Data triangulation and cross-functional peer reviews ensure accuracy and actionable insights.

Why This Report Matters

  • Supports stakeholders in refining R&D priorities and optimizing competitive positioning within the polycystic ovarian syndrome treatment market.
  • Provides actionable intelligence to guide regional strategy, procurement decisions, and tailored product development suited to unique patient or regulatory contexts.
  • Empowers leaders to anticipate policy, supply chain, and digital health trends impacting future market growth and patient access.

Conclusion

The polycystic ovarian syndrome treatment market is evolving rapidly, shaped by technology innovation, policy shifts, and changing clinical practices. Senior decision-makers equipped with these insights can proactively drive strategy and improve patient care outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid adoption of GLP-1 receptor agonists for weight management in PCOS patients
5.2. Integration of digital health platforms and telemedicine for personalized PCOS monitoring and care
5.3. Rising investment in non-hormonal therapies targeting insulin resistance and ovarian function
5.4. Expansion of nutraceutical and herbal supplement portfolios addressing hormonal balance in PCOS
5.5. Emergence of companion diagnostics for tailoring PCOS treatment based on genetic and metabolic biomarkers
5.6. Growth of patient-centric mobile applications for tracking menstrual cycles and symptom patterns in PCOS
5.7. Strategic partnerships between pharmaceutical companies and academic institutions for novel PCOS drug development
5.8. Increasing focus on combination therapies addressing metabolic and reproductive aspects of PCOS
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Polycystic Ovarian Syndrome Treatment Market, by Treatment Type
8.1. Introduction
8.2. Lifestyle Management
8.3. Pharmacological Treatment
8.4. Surgical Treatment
8.4.1. Bariatric Surgery
8.4.2. Ovarian Drilling
9. Polycystic Ovarian Syndrome Treatment Market, by Drug Class
9.1. Introduction
9.2. Anti-Androgens
9.2.1. Flutamide
9.2.2. Spironolactone
9.3. Insulin-Sensitizing Agents
9.3.1. Metformin
9.3.2. Thiazolidinediones
9.4. Oral Contraceptives
9.4.1. Combined Oral Contraceptives
9.4.2. Progestin-Only Pills
10. Polycystic Ovarian Syndrome Treatment Market, by Route Of Administration
10.1. Introduction
10.2. Injectable
10.2.1. Intramuscular Injection
10.2.2. Subcutaneous Injection
10.3. Oral
10.4. Topical
11. Polycystic Ovarian Syndrome Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Polycystic Ovarian Syndrome Treatment Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Homecare Settings
12.4. Hospitals
12.5. Specialty Centers
13. Polycystic Ovarian Syndrome Treatment Market, by Patient Type
13.1. Introduction
13.2. Adolescents
13.2.1. 16 To 18 Years
13.2.2. Under 18 Years
13.3. Adults 18-35
13.4. Adults 36-45
14. Americas Polycystic Ovarian Syndrome Treatment Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Polycystic Ovarian Syndrome Treatment Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Bayer AG
17.3.2. Teva Pharmaceutical Industries Ltd.
17.3.3. Viatris Inc.
17.3.4. Ferring International Center S.A.
17.3.5. Dr. Reddy’s Laboratories Limited
17.3.6. GlaxoSmithKline plc
17.3.7. Merck KGaA
17.3.8. Novartis AG
17.3.9. Pfizer Inc.
17.3.10. Sun Pharmaceutical Industries Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET: RESEARCHAI
FIGURE 28. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 29. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 30. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY OVARIAN DRILLING, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY OVARIAN DRILLING, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY FLUTAMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY FLUTAMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SPIRONOLACTONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SPIRONOLACTONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY METFORMIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY METFORMIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY 16 TO 18 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY 16 TO 18 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY UNDER 18 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY UNDER 18 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADULTS 18-35, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADULTS 18-35, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADULTS 36-45, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADULTS 36-45, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 147. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 148. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 149. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 150. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 151. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 152. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 153. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2024 (USD MILLION)
TABLE 154. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2025-2030 (USD MILLION)
TABLE 155. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2024 (USD MILLION)
TABLE 156. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2025-2030 (USD MILLION)
TABLE 157. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
TABLE 158. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2025-2030 (USD MILLION)
TABLE 159. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 162. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 163. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 168. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 169. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2024 (USD MILLION)
TABLE 170. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2025-2030 (USD MILLION)
TABLE 171. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 172. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 173. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 174. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 175. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 176. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 177. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2024 (USD MILLION)
TABLE 178. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2025-2030 (USD MILLION)
TABLE 179. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2024 (USD MILLION)
TABLE 180. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2025-2030 (USD MILLION)
TABLE 181. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
TABLE 182. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2025-2030 (USD MILLION)
TABLE 183. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 186. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 187. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 192. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 193. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2024 (USD MILLION)
TABLE 194. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENTS, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 274. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2018-2024 (USD MILLION)
TABLE 276. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY ANTI-ANDROGENS, 2025-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SIZE, BY INSULIN-SENSITIZING AGENTS, 2018-2024 (USD MILLION)
TABLE 278. UNITED KINGDOM POLYCY

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Polycystic Ovarian Syndrome Treatment market report include:
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Ferring International Center S.A.
  • Dr. Reddy’s Laboratories Limited
  • GlaxoSmithKline plc
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.68 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.09 Billion
Compound Annual Growth Rate6.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Polycystic Ovarian Syndrome Treatment Market Size, Share & Trends Analysis Report by Drug Class (Oral Contraceptives, Antiandrogens, Insulin-sensitizing Agent, Antidepressant, Anti-obesity), Surgery, Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Image

Polycystic Ovarian Syndrome Treatment Market Size, Share & Trends Analysis Report by Drug Class (Oral Contraceptives, Antiandrogens, Insulin-sensitizing Agent, Antidepressant, Anti-obesity), Surgery, Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Polycystic Ovarian Syndrome Treatment Market Report 2025 - Product Image

Polycystic Ovarian Syndrome Treatment Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Polycystic Ovarian Syndrome - Pipeline Insight, 2025 - Product Image

Polycystic Ovarian Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Polycystic Ovarian Syndrome Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Polycystic Ovarian Syndrome Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 86 Pages
  • Global
From
Polycystic Ovary Syndrome (PCOS) Treatment - Global Strategic Business Report - Product Image

Polycystic Ovary Syndrome (PCOS) Treatment - Global Strategic Business Report

  • Report
  • 360 Pages
  • Global
From

About the Polycystic Ovary Syndrome Drug Market

Polycystic Ovary Syndrome (PCOS) is a hormonal disorder that affects women of reproductive age. It is characterized by irregular menstrual cycles, excess androgen production, and the formation of cysts on the ovaries. PCOS is a leading cause of infertility and can increase the risk of developing ovarian cancer. Drugs used to treat PCOS are typically hormone-based, such as oral contraceptives, anti-androgens, and gonadotropin-releasing hormone agonists. These drugs are used to regulate hormones, reduce androgen levels, and improve fertility. Additionally, lifestyle modifications such as diet and exercise are recommended to help manage PCOS symptoms. The PCOS drug market is highly competitive, with a range of products available from both generic and branded manufacturers. Companies such as Pfizer, Merck, and Novartis are some of the major players in the market. Other companies include Bayer, Sanofi, and Allergan. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.